Help for children with diabetes
Toronto Star, Canada -
Upgrading Ontario�s out-dated public health laboratories is also a priority. About $31 million over three years will be spent to relocate �a significant component� of the Central Public Health Laboratory in Toronto and upgrade other regional health labs. The Ontario-run health labs were recently assessed by consultants and found to be outdated and in need of an overhaul in order to handle emerging infectious diseases.
2006-03-23
PhytoMedical Enters Into Expanded Collaborative Agreement For Type
Genetic Engineering News, NY -
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
2006-03-20
Medtronic boosts diabetes care
Trade Arabia, Bahrain -
Worldwide it is estimated there are approximately 194 million adults with diabetes and this number is expected to reach 333 million by the year 2025. Much of this increase will occur in developing countries and will be due to population growth, ageing, unhealthy diets, obesity and sedentary lifestyles.
2006-03-19
Callaway's diabetes rate prompts health fair
Fulton Sun, USA -
“They're aware of the word diabetes and they think of low blood sugar, but there's also the possibility of a loss of life, loss of sight and loss of limb,” he said. “It's a safe bet you'll feel better if you're not alone. � If you know of people who are going through the same thing and have been successful, it can provide hope - and hope is a wonder drug.”
2006-03-18
Parkinson's, Alzheimer's, and Diabetes Are Just Some of the
Genetic Engineering News, NY -
-- Dozens of stem-cell companies are competing with one another and seeking collaborations with big pharmaceutical companies. Although the technology in these companies is still primarily in the research phase, some groups have demonstrated proof-of-concept for stem-cell technologies in animal models. Those companies that ultimately control the rights to stem cells and their uses will become dominant players. Companies that conduct stem-cell-based drug discovery and product development will achieve the greatest value.
2006-03-17
Parkinson's, Alzheimer's, and Diabetes Are Just Some of the
Genetic Engineering News, NY -
-- Dozens of stem-cell companies are competing with one another and seeking collaborations with big pharmaceutical companies. Although the technology in these companies is still primarily in the research phase, some groups have demonstrated proof-of-concept for stem-cell technologies in animal models. Those companies that ultimately control the rights to stem cells and their uses will become dominant players. Companies that conduct stem-cell-based drug discovery and product development will achieve the greatest value.
2006-03-16
eFoodSafety.com, Inc. Commences Distribution of Cinnergen Diabetes
Genetic Engineering News, NY -
eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.
1. Diabetes & dairy products
Q I try to do everything possible to keep my diabetes under control. Can you give me information about the connection between diabetes and dairy products?
2. New form of diabetes may damage the brain
DIABETES AND ALZHEIMER''S disease may be related, but not in the way many researchers have suspected. Scientists have long believed insulin was produced ...
3. Diabetes'' ''littlest victims'': youth advocate recounts his life with the disease- and his hope for the future
My name is Gilles Attipoe. I am 12 years old and I have had diabetes for more than half my life. I was diagnosed when I was 5. Since then, I have had ...
4. Diabetes treatment, research & cure
IT''S the fifth deadliest disease in the United States, and it has no cure. In fact, diabetes has become so insidious--striking more people than ever, ...
5. Diabetes special section
THIS special section represents an important milestone as the American Diabetes Association (ADA) celebrates its 10th anniversary in providing increased ...